Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Tiffany Wang

Physician Assistant Arcadia, CA Physician Assistant

NPI 1043855083 CMS profile 10558457

2031 S 8Th Ave, Arcadia, CA 91006

Open in the dashboard

General payments

$12,273

479 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Tiffany Wang of Arcadia, CA is reported in the CMS Open Payments database as having received $12,273 across 479 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,734 44
2024 General $2,767 125
2023 General $3,794 135
2022 General $2,015 76
2021 General $1,962 99

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Tiffany Wang
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Tiffany Wang were reported at $1,734. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Tiffany Wang Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $1,962 $132 $37–$438 $132
2022 $2,015 $155 $48–$522 $149
2023 $3,794 $167 $52–$557 $160
2024 $2,767 $178 $55–$600 $164
2025 $1,734 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Galderma Laboratories, L.P. $2,033 84 payments
  2. AbbVie, Inc. $1,833 76 payments
  3. Sun Pharmaceutical Industries Inc. $1,567 66 payments
  4. Genzyme Corporation $956 24 payments
  5. Incyte Corporation $951 44 payments
  6. Dermavant Sciences, Inc. $708 14 payments
  7. Lilly USA, LLC $537 13 payments
  8. Janssen Biotech, Inc. $525 27 payments
  9. Revance Therapeutics, Inc. $470 6 payments
  10. Regeneron Healthcare Solutions, Inc. $433 15 payments
  11. Other $2,261 110 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $11,955 475 payments
  2. Education $318 4 payments
Products named General payments · program years 2021–2025
  1. DUPIXENT $1,592 37 payments
  2. OPZELURA $881 43 payments
  3. Winlevi $738 33 payments
  4. VTAMA $724 16 payments
  5. BOTOX $691 21 payments
  6. ILUMYA $567 19 payments
  7. TREMFYA $525 27 payments
  8. SKYRIZI $485 27 payments
  9. DAXXIFY $438 5 payments
  10. AKLIEF $430 18 payments
  11. Other $5,679 250 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

479 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record